Gene patents: a crowded IP field

Since the end of the first era of genome sequencing with the conclusion of the human genome project, the challenge facing the life sciences industry has been to apply our understanding to practical applications.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Novartis bets $2bn on biologics as Xolair patents fade

27 March 2026 The Swiss pharma giant targets next-generation anti-IgE biologics as it looks to extend its dominance in the market.

Europe

WIPR debuts Global In-House Elite 2026

26 March 2026 LSIPR sister title launches vetted list celebrating leading in-house counsel who demonstrate exceptional ability in managing their organisation's IP portfolio, legal team, and IP culture.

Biotechnology

mRNA litigation: Who’s winning, who’s filing, and what’s next

25 March 2026 As the world moves past the pandemic, a massive legal struggle over the future of mRNA technology is just hitting its stride. LSIPR visualises the litigation defining the next era.

More features

Abbott IP chief: ‘Firms without AI policies scare me’

Emotional Perception: What next for patent holders?

Rooted in rights: Lessons from plant patent infringement and invalidity cases

How AI will be shaped by legal and regulatory developments in 2026

Key EU and UK regulatory changes to watch for in 2026

Regeneron v Alvotech: The big impact

Beyond traditional IP: A comprehensive AI strategy for life sciences

Prosecuting bispecific antibody patents: A cookbook for patent chefs

Gene patents: a crowded IP field

More on this story

Editor's picks

Editor's picks

More features